Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Nephrology 3, 426–427 (1 August 2007) | doi:10.1038/ncpneph0540
Minimizing ciclosporin in renal transplant recipients on daclizumab, mycophenolate and steroids
&
Abstract
Ekberg H et al. (2007) Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 7: 560–570 Synopsis Background There is great interest in reducing exposure of renal transplant recipients to the nephrotoxic effects of calcineurin inhibitors.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
